Literature DB >> 12611974

Human amylin actions on rat cholinergic basal forebrain neurons: antagonism of beta-amyloid effects.

Jack H Jhamandas1, Kim H Harris, Caroline Cho, Wen Fu, David MacTavish.   

Abstract

Human amylin (hAmylin), a 37-amino acid pancreatic peptide, and amyloid beta protein (A beta), a 39-43 amino acid peptide, abundantly deposited in the brains of Alzheimer's patients, induce neurotoxicity in hippocampal and cortical cultures. Although the mechanism of this neurotoxicity is unknown, both peptides are capable of modulating ion channel function that may result in a disruption of cellular homeostasis. In this study, we examined the effects of hAmylin on whole cell currents in chemically identified neurons from the rat basal forebrain and the interactions of hAmylin-induced responses with those of A beta. Whole cell patch-clamp recordings were performed on enzymatically dissociated neurons of the diagonal band of Broca (DBB), a cholinergic basal forebrain nucleus. Bath application of hAmylin (1 nM to 5 microM) resulted in a dose-dependent reduction in whole cell currents in a voltage range between -30 and +30 mV. Single-cell RT-PCR analysis reveal that all DBB neurons responding to hAmylin or A beta were cholinergic. Using specific ion channel blockers, we identified hAmylin and A beta effects on whole cell currents to be mediated, in part, by calcium-dependent conductances. Human amylin also depressed the transient outward (IA) and the delayed rectifier (IK) potassium currents. The hAmylin effects on whole cell currents could be occluded by A beta and vice versa. Human amylin and A beta responses could be blocked with AC187 (50 nM to 1 microM), a specific antagonist for the amylin receptor. The present study indicates that hAmylin, like A beta, is capable of modulating ion channel function in cholinergic basal forebrain neurons. Furthermore, the two peptides may share a common mechanism of action. The ability of an amylin antagonist to block the responses evoked by hAmylin and A beta may provide a novel therapeutic approach for Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12611974     DOI: 10.1152/jn.01138.2002

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  6 in total

1.  Actions of β-amyloid protein on human neurons are expressed through the amylin receptor.

Authors:  Jack H Jhamandas; Zongming Li; David Westaway; Jing Yang; Simran Jassar; David MacTavish
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

2.  Proteolytic processing of SDF-1alpha reveals a change in receptor specificity mediating HIV-associated neurodegeneration.

Authors:  David Vergote; Georgina S Butler; Martine Ooms; Jennifer H Cox; Claudia Silva; Morley D Hollenberg; Jack H Jhamandas; Christopher M Overall; Christopher Power
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-05       Impact factor: 11.205

Review 3.  Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease.

Authors:  Satyabrata Kar; Stephen P M Slowikowski; David Westaway; Howard T J Mount
Journal:  J Psychiatry Neurosci       Date:  2004-11       Impact factor: 6.186

Review 4.  Overcoming barriers and thresholds - signaling of oligomeric Aβ through the prion protein to Fyn.

Authors:  Hansen Wang; Carl He Ren; C Geeth Gunawardana; Gerold Schmitt-Ulms
Journal:  Mol Neurodegener       Date:  2013-07-16       Impact factor: 14.195

5.  Amylin receptor: a common pathophysiological target in Alzheimer's disease and diabetes mellitus.

Authors:  Wen Fu; Aarti Patel; Jack H Jhamandas
Journal:  Front Aging Neurosci       Date:  2013-08-15       Impact factor: 5.750

6.  Notoginsenoside R1 increases neuronal excitability and ameliorates synaptic and memory dysfunction following amyloid elevation.

Authors:  Shijun Yan; Zhi Li; Hang Li; Ottavio Arancio; Wensheng Zhang
Journal:  Sci Rep       Date:  2014-09-12       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.